Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Editas Medicine (EDIT)

$2.60 +0.04 (1.56%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	214.31M
Revenue (ttm)	32.31M
Net Income (ttm)	-237.09M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-733.80%
Debt to Equity Ratio	0.00

Volume	1,618,000
Avg Vol	2,690,042
Day's Range	N/A - N/A
Shares Out	83.71M
Stochastic %K	19%
Beta	2.19
Analysts	Sell
Price Target	$3.11

Company Profile

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in No...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 401 9000

Website: www.editasmedicine.com

Address:

11 Hurley Street, Cambridge, United States

WallStreetBuyDip Aug. 3 at 6:24 AM

$EDIT trading at $2 with volume 40% below average, while $VRTX sitting at $462 with 30% above average volume. VRTX showing strength compared to EDIT. Are Genomics stocks like these ready for a breakout?

0 · Reply

3DBuilds Aug. 2 at 12:49 AM

$EDIT

1 · Reply

Whoami1989 Aug. 1 at 8:13 PM

$EDIT Pathetic

0 · Reply

Whoami1989 Aug. 1 at 4:02 PM

$EDIT the worst of the worse

0 · Reply

3DBuilds Jul. 31 at 11:52 PM

$EDIT buy buy buy $$$

0 · Reply

jonecho49 Jul. 31 at 2:00 PM

$EDIT Well. I guess the billionaire class mems have moved on!

0 · Reply

Whoami1989 Jul. 31 at 1:57 PM

$EDIT the most pathetic and vomiting stock on the planet

1 · Reply

0x126 Jul. 31 at 1:32 PM

$EDIT US guys, this sector drop related to fed?

1 · Reply

3DBuilds Jul. 30 at 9:04 PM

$EDIT

0 · Reply

Whoami1989 Jul. 30 at 7:49 PM

$EDIT mf pos

0 · Reply

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

May 20, 2025, 5:47 AM EDT - 2 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT NTLA VANI VERV

May 14, 2025, 2:17 PM EDT - 2 months ago

Editas Medicine, Inc. (EDIT) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 9:31 AM EDT - 2 months ago

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June

May 14, 2025, 7:01 AM EDT - 2 months ago

Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting

May 13, 2025, 7:01 AM EDT - 3 months ago

Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting

May 12, 2025, 4:30 PM EDT - 3 months ago

Editas Medicine Announces First Quarter 2025 Results and Business Updates

May 12, 2025, 4:01 PM EDT - 3 months ago

Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board

May 5, 2025, 4:01 PM EDT - 3 months ago

Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May

Apr 28, 2025, 4:31 PM EDT - 3 months ago

Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

Mar 20, 2025, 4:01 PM EDT - 4 months ago

Editas Medicine Announces Chief Financial Officer Transition

Mar 11, 2025, 4:07 PM EDT - 5 months ago

Editas Medicine, Inc. (EDIT) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 10, 2025, 12:19 PM EDT - 5 months ago

Editas Medicine, Inc. (EDIT) Leerink Partners Global Healthcare Conference (Transcript)

Mar 5, 2025, 4:05 PM EST - 5 months ago

Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates

Mar 3, 2025, 5:01 PM EST - 5 months ago

Editas Medicine, Inc. (EDIT) TD Cowen 45th Annual Health Care Conference Transcript

Feb 24, 2025, 9:00 AM EST - 5 months ago

Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March

Jan 17, 2025, 12:20 PM EST - 7 months ago

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

NTLA

Jan 15, 2025, 4:35 PM EST - 7 months ago

Editas Medicine, Inc. (EDIT) 43rd Annual JPMorgan Healthcare Conference - (Transcript)

Jan 13, 2025, 9:00 AM EST - 7 months ago

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Jan 6, 2025, 9:00 AM EST - 7 months ago

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 6:44 AM EST - 8 months ago

Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026

Dec 12, 2024, 6:03 PM EST - 8 months ago

Editas to reduce about 65% of its workforce over the next six months

Dec 12, 2024, 4:00 PM EST - 8 months ago

Editas Medicine Announces Strategic Transition to in vivo Gene Editing Company with Intent to Achieve Human Proof of Concept in Approximately Two Years

Dec 9, 2024, 12:00 PM EST - 8 months ago

Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting

Dec 3, 2024, 10:52 PM EST - 8 months ago

Editas Medicine, Inc. (EDIT) 7th Annual Evercore HealthCONx Conference (Transcript)

Nov 25, 2024, 12:59 PM EST - 9 months ago

Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts

Nov 19, 2024, 7:53 PM EST - 9 months ago

Editas Medicine, Inc. (EDIT) Presents at Stifel 2024 Healthcare Conference (Transcript)

Nov 6, 2024, 9:00 AM EST - 9 months ago

Editas Medicine to Participate in Upcoming Investor Conferences

Nov 4, 2024, 7:30 AM EST - 9 months ago

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Oct 22, 2024, 11:45 AM EDT - 10 months ago

Editas Medicine, Inc. (EDIT) Strategic Update Call Transcript

Oct 21, 2024, 4:30 PM EDT - 10 months ago

Editas Medicine and Genevant Sciences to Collaborate to Develop Novel mRNA-LNP Gene Editing Therapeutics

Oct 18, 2024, 4:01 PM EDT - 10 months ago

Editas Medicine to Host Strategic Update Webinar to Detail Progress Towards 2024 Goals, Including Achievement of Establishing In Vivo Preclinical Proof of Concept

Oct 7, 2024, 3:33 PM EDT - 10 months ago

Editas Medicine (EDIT) Shares Plunge Amid Biotech Sector Fluctuations

Oct 6, 2024, 2:00 PM EDT - 10 months ago

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

AMGN BIIB BLUE BMY CRSP EXAS NTLA

Oct 3, 2024, 6:00 PM EDT - 10 months ago

Editas Medicine Announces $50+ Million Monetization Financing with DRI Healthcare Trust

Oct 1, 2024, 7:53 PM EDT - 11 months ago

Editas Medicine, Inc. (EDIT) Chardan's 8th Annual Genetic Medicines Conference (Transcript)

Sep 25, 2024, 11:46 AM EDT - 11 months ago

Editas Medicine: A Risk/Reward Worth Considering

Sep 17, 2024, 5:26 PM EDT - 11 months ago

Editas Medicine, Inc. (EDIT) 2024 Cantor Global Healthcare Conference (Transcript)

Sep 5, 2024, 11:19 PM EDT - 11 months ago

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)

Sep 4, 2024, 7:17 PM EDT - 11 months ago

Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

Aug 7, 2024, 12:03 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

Jul 31, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update

Jun 14, 2024, 3:01 AM EDT - 1 year ago

Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress

Jun 14, 2024, 3:00 AM EDT - 1 year ago

Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress

May 15, 2024, 8:25 PM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) RBC Capital Markets Global Healthcare Conference (Transcript)

May 14, 2024, 10:00 AM EDT - 1 year ago

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June

May 10, 2024, 6:00 AM EDT - 1 year ago

Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting

May 8, 2024, 10:57 AM EDT - 1 year ago

Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

Editas Medicine Announces First Quarter 2024 Results and Business Updates

WallStreetBuyDip Aug. 3 at 6:24 AM

0 · Reply

3DBuilds Aug. 2 at 12:49 AM

$EDIT

1 · Reply

Whoami1989 Aug. 1 at 8:13 PM

$EDIT Pathetic

0 · Reply

Whoami1989 Aug. 1 at 4:02 PM

$EDIT the worst of the worse

0 · Reply

3DBuilds Jul. 31 at 11:52 PM

$EDIT buy buy buy $$$

0 · Reply

jonecho49 Jul. 31 at 2:00 PM

$EDIT Well. I guess the billionaire class mems have moved on!

0 · Reply

Whoami1989 Jul. 31 at 1:57 PM

$EDIT the most pathetic and vomiting stock on the planet

1 · Reply

0x126 Jul. 31 at 1:32 PM

$EDIT US guys, this sector drop related to fed?

1 · Reply

3DBuilds Jul. 30 at 9:04 PM

$EDIT

0 · Reply

Whoami1989 Jul. 30 at 7:49 PM

$EDIT mf pos

0 · Reply

heydrsam Jul. 30 at 1:33 PM

$EDIT https://www.reuters.com/business/healthcare-pharmaceuticals/us-fdas-top-vaccine-official-vinay-prasad-leaves-agency-after-short-stint-2025-07-30/

0 · Reply

RocroBio Jul. 30 at 4:12 AM

$EDIT $ABCL $CRSP $CRBU https://whop.com/lstm-labs?a=rocrobio

0 · Reply

RocroBio Jul. 30 at 4:11 AM

$EDIT

0 · Reply

Whoami1989 Jul. 29 at 8:32 PM

$EDIT fpos period!!!

0 · Reply

NVDAMillionaire Jul. 29 at 7:07 PM

$EDIT Really good write-up that perfectly summarizes EDIT's present situation. So if you want to bring your EDIT knowledge up to date or just discover EDIT, this is required reading. https://beyondspx.com/article/editas-medicine-pivoting-to-in-vivo-fueled-by-differentiated-tech-and-extended-runway-edit

0 · Reply